Jan 3, 2017 ... Amgen Inc. et al v. Sanofi et al, No. 1:2014cv01317 - Document 389 (D. Del. 2017) case opinion from the District of Delaware US Federal District Court.
Rangel v. Sanofi Aventis, No. 12-3085 (10th Cir. 2013) case opinion from the U.S. Court of Appeals for the Tenth Circuit.
Rangel v. Sanofi Aventis U.S., LLC et al, No. 6:2010cv01359 - Document 39 (D. Kan. 2012) case opinion from the District of Kansas US Federal District Court.
Apr 15, 2012 ... accord Pettit v. Pulte Mortg., LLC, No. 2:11-cv-00149-GMN-PAL, 2011 WL. 5546422, at *5 (D. Nev. Nov. 14, 2011) (“Discovery is expensive.”). 10. Moore's. Law. Inspires .... 33. See id. 34. See Paul W. Grimm et al., Proportionality in the Post-Hoc Analysis of Pre- ... e.g., Eisai Inc. v. Sanofi-Aventis U.S., LLC,.
Oct 18, 2017 ... because they failed to so move, despite multiple opportunities to do so, including: • Following the grant of Amgen's JMOL on non-obviousness in the middle of the trial, Amgen rested. (Tr. 1100:19-20.) Defendants said nothing about a Rule. 50(a ) motion and immediately began their rebuttal case.
T-17-16, DUCKS LANE LTD. ET AL v. OUTFORONT MEDIA LLC ET AL, Trade Mark Infringement, 2016-11-28, Bennett Jones LLP; HUSSEY, DOMINIQUE T;. T- 20-16 ... ET AL. v. MUNCHKIN, INC ET AL. Patent Infringement, 2016-01-22, Oslers; Smart & Biggar. T-153-16, AMERICAN AUTOMOBILE ASSOCIATIONS, INC. v.
See United States v. Procter & Gamble Co., 356 U.S. 677,682 (1958) (explain- ing that discovery is designed to "make a trial less a game ofblindman's buff and more a fair contest with the ... Eisai Inc. v. Sanofi-Aventis U.S., LLC, .... See Grimm et al., supra note 34, at 392 (lamenting the complexities that organi- zations face ...
Hammer et al. (63) analyzed BG levels among 1,175 adult patients receiving allogeneic hematopoietic cell transplants. Hyperglycemia, hypoglycemia, and glycemic ..... G.E.U. reports that he has received consultant fees from Merck & Co. , Inc., and consultant fees and research grant support from sanofi-aventis U.S. LLC.
We included all knee OA trials which compared any of the 18 HA products and reported on adverse events (AEs) and withdrawals. .... All included trials were published between 1983 and 2015 and involved a total of 13,032 randomized participants. ..... This research was supported by a grant from Sanofi Aventis US, LLC.